AB Science today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma

World News: . []

The phase 3 trial AB08026 was an open-label controlled study comparing LINK  to dacarbazine and designed to assess the LINK  and efficacy of masitinib 75 mgkgday in LINK  with non-resectable or metastatic stage 3 or stage 4 melanoma ca rrying ...

More news and information about AB Science

Published By:

Globe Newswire: 16:44 GMT Friday 2nd August 2019

Published: .

Search for other references to "science" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us